نتایج جستجو برای: melphalan

تعداد نتایج: 4419  

Journal: :Biology of Blood and Marrow Transplantation 2012

مکاری زاده , آرام, دلیرژ , نوروز , مرشدی, احمد , پروین, پروا,

 Background & Aims: Dendritic cells are the most potent antigen presenting cells in induction or polarization of T-dependent immune responses. In cancerous patients, suppressive or detoured immune responses regard to tumor cells, prevent appropriate functions of dendritic cells. Nowadays, in vitro production, expansion and maturation of dendritic cells in presence of safe maturation factors whi...

2017

Autologous Stem Cell Transplantation (ASCT) is a standard of care in relapsed diffuse large B-cell lymphoma (DLBCL) and other lymphoproliferative disorders including relapsed Hodgkin’s disease, mantle or T-cell lymphoma. Carmustine, etoposide, ARA-C, melphalan (BEAM) [1], lomustine, etoposide, ARA-C, melphalan (LEAM) and lomustine, ARA-C, cyclophosphamide, etoposide (LACE) are commonly used con...

2016
Cirino Botta Maria Rita Pitari Santo Giovanni Lio Domenico Britti Maria Angelica Stamato Teru Hideshima Nikhil C. Munshi Kenneth C. Anderson Pierosandro Tagliaferri Pierfrancesco Tassone

Purpose: The onset of drug resistance is a major cause of treatment failure in multiple myeloma. Although increasing evidence is defining the role of miRNAs in mediating drug resistance, their potential activity as drug-sensitizing agents has not yet been investigated in multiple myeloma. Experimental Design: Here we studied the potential utility of miR-221/222 inhibition in sensitizing refract...

2008
A. F. BROAD E. W. EMERY

Thirty-six out of sixty-two cases of myelomatosis have been treated with melphalan. Platelet counts were used as a guide to dosage early in the course of treatment, after which a more empirical dosage (0-15 mg/kg/ day) was used in 1-week courses given every 12 weeks. Rapid deterioration and death occur in a small number of patients whatever therapy is given. In the group treated with melphalan ...

Journal: :Postgraduate medical journal 1988
J D Walker R S Kaczmarski

In the majority of cases plasma cell leukaemia is a rapidly fatal disease with a mean survival time of five months. There have been reports of increased survival using various regimens of chemotherapy although most cases eventually relapse. We describe a patient with primary plasma cell leukaemia who responded to a combination of oral melphalan and prednisolone with control of the disease in th...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید